Target Name: NME1
NCBI ID: G4830
Review Report on NME1 Target / Biomarker Content of Review Report on NME1 Target / Biomarker
NME1
Other Name(s): NM23 | Granzyme A-activated DNase | NDK A | NDKPA | epididymis secretory sperm binding protein | AWD | Nucleoside diphosphate kinase A (isoform a) | NDKA | NB | non-metastatic cells 1, protein (NM23A) expressed in | Nm23-H1 | GAAD | NDPKA | NDP kinase A | NDPK-A | NM23-H1 | metastasis inhibition factor nm23 | tumor metastatic process-associated protein | NME/NM23 nucleoside diphosphate kinase 1 | NBS | Tumor metastatic process-associated protein | NME/NM23 nucleoside diphosphate kinase 1, transcript variant 1 | Metastasis inhibition factor nm23 | Nucleoside diphosphate kinase A | NME1 variant 1 | granzyme A-activated DNase | NDKA_HUMAN

Identification and Characterization of NME1 as A Potential Drug Target and Biomarker

NME1, or N-methyl-L-alanine aminotransferase 1, is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the protein family G, which includes a variety of enzymes that are involved in the transfer of amino acids from the cell to the cell.

One of the functions of NME1 is to regulate the levels of amino acids in the brain, particularly the amino acid L-alanine. L-alanine is an important precursor of the neurotransmitter acetylcholine, which is involved in memory and learning. NME1 is also involved in the metabolism of other amino acids, including GABA, which is a neurotransmitter that is involved in the regulation of mood and behavior.

In addition to its role in regulating amino acid levels, NME1 is also involved in the regulation of cellular signaling pathways. It is a target for several different signaling pathways, including the TOR signaling pathway and the NF-kappa-B signaling pathway. These pathways are involved in a variety of cellular processes, including cell growth, apoptosis (programmed cell death), and inflammation.

Due to its involvement in these signaling pathways, NME1 is a potential drug target for a variety of diseases. One of the primary goals of drug development is to identify small molecules that can inhibit the activity of NME1 and prevent it from participating in these signaling pathways. These small molecules can then be used to treat a variety of diseases, including neurodegenerative disorders, psychiatric disorders, and inflammatory diseases.

In addition to its potential as a drug target, NME1 is also a potential biomarker for a variety of diseases. The levels of NME1 have been shown to be elevated in the brains of individuals with a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, NME1 has been shown to be elevated in the blood of individuals with certain psychiatric disorders, such as depression and anxiety. These findings suggest that NME1 may be a useful biomarker for a variety of psychiatric and neurological disorders.

Overall, NME1 is a protein that is involved in a variety of cellular processes throughout the body. Its role in regulating amino acid levels and cellular signaling pathways makes it a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the function and potential of NME1 and its implications for human health.

Protein Name: NME/NM23 Nucleoside Diphosphate Kinase 1

Functions: Major role in the synthesis of nucleoside triphosphates other than ATP. The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Possesses nucleoside-diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease activities. Involved in cell proliferation, differentiation and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. Required for neural development including neural patterning and cell fate determination. During GZMA-mediated cell death, works in concert with TREX1. NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair

The "NME1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NME1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NME1-NME2 | NME2 | NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12 | NOL3 | NOL4 | NOL4L | NOL4L-DT | NOL6 | NOL7 | NOL8 | NOL9 | NOLC1 | NOM1 | NOMO1 | NOMO2 | NOMO3 | Non-protein coding RNA 185 | NONO | NOP10 | NOP14 | NOP14-AS1 | NOP16 | NOP2 | NOP53 | NOP56 | Nop56p-associated pre-rRNA complex | NOP58 | NOP9 | NOPCHAP1 | NORAD | NOS1 | NOS1AP | NOS2 | NOS2P1 | NOS2P2 | NOS2P3 | NOS3 | NOSIP | NOSTRIN | Notch ligands | Notch receptor | Notch Transcriptional Activation Complex | NOTCH1 | NOTCH2 | NOTCH2NLA | NOTCH2NLC | NOTCH3 | NOTCH4 | NOTO | NOTUM | NOVA1 | NOVA1-DT | NOVA2 | NOX1 | NOX3 | NOX4 | NOX5